TECHNOLOGY


OUR SENZA5TM PLATFORM TECHNOLOGY IS PRODUCING INNOVATIVE, DIFFERENTIATED,
ENABLED AUTOLOGOUS CELL THERAPIES

Senza5 for differentiated, enabled autologous cell therapy
Senza5 harnesses CD5 as a T-cell enhancer

SIGNALING MODULATION

Central to our discovery and development efforts is Senza5, a first-in-class modular platform technology designed to enhance efficacy in the emerging segment of enabled, autologous engineered T-cell therapies which will shape the next generation of cellular therapies.

Laboratory studies in multiple liquid and solid tumor models show that Senza5 CAR T-cells have significantly improved efficacy compared to conventional CAR T-cell therapies. Our lead program, VIPER-101, is currently in the clinic and will provide a read-through into the clinical benefits of Senza5 technology.

SENZA5 HARNESSES THE UNREALIZED POTENTIAL OF CD5 AS A T-CELL ENHANCER

Senza5 harnesses CD5 as a T-cell enhancer
Senza5 harnesses CD5 as a T-cell enhancer

Senza5 manufacturing uses a patient’s own T-cells and engineers them to eliminate CD5 signaling while adding a chimeric antigen receptor (CAR) which allows T-cells to find and eliminate a target cell. These “supercharged” T-cells are then infused back into the patient and can lead to increased:

  • T-cell activation and proliferation
  • T-cell–mediated cytotoxicity
  • Cytokine and chemokine secretion
  • Resistance to exhaustion
  • Enhanced “Stemness”

Proprietary 5-day manufacturing process

Proprietary MANUFACTURING PROCESS

Proprietary 5-day manufacturing process.
Proprietary 5-day manufacturing process.

In the fight against cancer, time is of the essence. Traditional CAR T-cell therapies, while groundbreaking, are often constrained by lengthy manufacturing timelines, typically spanning 14 days or more. Vittoria’s expedited manufacturing process shortens that timeline to 5 days, which can reduce manufacturing costs and improve vein-to-vein times. Our rapid manufacturing process synergizes with our CD5 modulation to further enhance cellular function by conferring enhanced stemness, which promotes robust in vivo expansion and resistance to exhaustion for longer-lasting responses.

ADDITIONAL TECHNOLOGIES are in development

Senza5 is our most advanced platform technology, but we have others in development as part of our commitment to innovation and differentiation in immunotherapy.